Read past a research label.

The FDA looks beyond the label

The Food and Drug Administration (FDA) regulates drugs in the US.

In March and August 2026, the FDA sent warning letters about products labelled for research. The sellers’ websites described using those products to treat people.

The letters accused those companies of selling unapproved new drugs against federal law. These were FDA accusations, not decisions by a court (checked September 2026).

A label and a treatment pitch can say different things. A research label does not answer your care questions.

Ask about the actual evidence

A study link raises useful questions. Was the study in people? Did it examine the same substance and form? What did the study measure? Ask the clinician to explain how it relates to your goal.

Keep a finding separate from a sales-page summary of that finding. If a headline says a medicine works, ask what result sits behind that statement.

Missing approval does not answer every question

Drugs@FDA is the FDA’s online list of drug approval records. A September 2026 search found no application record for the peptides named BPC-157, ipamorelin, or retatrutide. There was no approved US medicine under those names.

The missing record does not show that the FDA rejected an application. It also does not review every study or every possible harm.

Ask the clinician about the specific substance being offered.

A product listing in the FDA’s drug list has a National Drug Code, or NDC, to identify it. It does not show FDA approval or prove that the FDA checked the information (checked September 2026).

An Idaho packaging question

Idaho’s patient guidance, checked September 2026, asks people to see the original package before an injection and check for an English label without research-use wording.

This is board guidance, not a separate law. Bring the product name and any study link to the clinician conversation rather than trying to turn a research page into a treatment plan.